Head-to-head evidence
Apomorphine sublingual film (Kynmobi) vs rotigotine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine · full Parkinson's Disease pipeline
Apomorphine sublingual film (Kynmobi)
Marketed by Sumitomo Pharma
NCT02469090 · Phase 3 · completed
The study randomized 109 patients to apomorphine sublingual film or matching placebo in a quadruple-blind design, with 54 patients receiving apomorphine and 55 receiving placebo. The primary clinical motor-function endpoint was met: the MDS-UPDRS Part III score improved more with apomorphine than placebo at Week 12 (p=0.0002).
rotigotine · Neupro
Marketed by UCB
NCT00244387 · Phase 3 · completed
Although the registry reports a randomized, double-blind design with 506 participants, it lists no comparator arm, so the treatment cannot be evaluated against another treatment or placebo from the available record. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Apomorphine sublingual film (Kynmobi)'s landscape · rotigotine's landscape